HMN 2025: How useful is Remibrutinib for urticaria after H1-antihistamine therapy

For sufferers with symptomatic persistent spontaneous urticaria after therapy with second-generation H₁-antihistamines, administration of the oral, extremely selective Bruton’s tyrosine kinase inhibitor, remibrutinib, ends in a big enchancment in a composite measure of itching and hives at week 12, in line with a review published within the March 6 challenge of the New England Journal of Medicine.

Martin Metz, M.D., from Charité–Universitätsmedizin Berlin, and colleagues examined the efficacy and security of remibrutinib in sufferers with symptomatic persistent spontaneous urticaria after therapy with second-generation H₁-antihistamines within the an identical REMIX-1 and REMIX-2 trials.

Patients had been randomly assigned to obtain remibrutinib at a dose of 25 mg twice every day or placebo (313 and 157 sufferers, respectively, in REMIX-1; 300 and 155 sufferers, respectively, in REMIX-2). The change from baseline to week 12 within the urticaria exercise rating throughout a seven-day interval (UAS7), which consists of severity scores for itch and hives throughout one week, was assessed as the first finish mark.

The researchers discovered that in contrast with the placebo group, the remibrutinib group had a considerably higher lower within the UAS7 at week 12, which was sustained at week 24. Significantly extra sufferers within the remibrutinib group versus the placebo group had a UAS7 rating of 6 or decrease at week 12 (REMIX-1: 49.8 versus 24.8%; REMIX-2: 46.8 versus 19.6%) and a UAS7 rating of 0 (REMIX-1: 31.1 versus 10.5%; REMIX-2: 27.9 versus 6.5%). Adverse occasion charges had been related within the remibrutinib group and the placebo group, though petechiae had been reported in the next share of sufferers within the remibrutinib group than within the placebo group.

“These outcomes assist the efficacy and security of remibrutinib in sufferers with persistent spontaneous urticaria that remained symptomatic regardless of therapy with second-generation H₁-antihistamines,” the authors write.

The study was funded by Novartis, the producer of remibrutinib.